This1 Dec 2021 10:57
We are now able to progress the commercial evaluations of the product to selected partners and given its performance in our studies, we believe there remain substantial market opportunities that can be targeted. As recent news of the Omicron variant demonstrates, COVID-19 remains a significant issue in global health and thus rapid and accurate testing will remain a critical tool in managing the spread of the virus."
Plenty of funds now accumulated so the upside is very strong imo.